¹⁷⁷Lu-PSMA-617 in the treatment of metastatic castration-resistant prostate cancer: First 5 years of experience in Uruguay

Prostate cancer is the most frequent solid neoplasm in the world and the second leading cause of cancer death in our country. All underwent radio targeted therapy receiving doses of ¹⁷⁷Lu-PSMA-617 (7.4GBq every 6 weeks) for at least three cycles. Serial positron emission tomography/ computed tomography (PET/CT) scans were performed with gallium-68 (⁶⁸Ga)-PSMA-11, (¹⁸F)AIF-PSMA-11, or ¹⁸F PSMA- 1007 to confirm PSMA expression in metastatic lesions and evaluate response. ¹⁷⁷Lu-PSMA therapy is a promising option in the treatment of patients with mCRPC, whose survival and quality of life have not been improved despite the myriad treatments available. ⁶⁸Ga-PSMA-11, (¹⁸F)AIF-PSMA-11, and ¹⁸F-PSMA-1007 versus ¹⁷⁷Lu-PSMA prove to be similar diagnostic- tandems. Experience in our environment shows a benefit in overall survival, lesions progression, and pain relief. Datawas consistent with scientific evidence that determined the approval of this therapeutic line in our country.